Aldagen, Inc. Announces Participation in Breakout Sessions at 2009 Biotechnology Industry Organization (BIO) International Convention

DURHAM, NC--(Marketwire - May 18, 2009) - Aldagen, Inc. today announced that it will be participating in two Breakout Sessions during the 2009 BIO International Convention taking place in Atlanta.

On Tuesday, May 19 at 2:00 pm, Andrew E. Balber, Ph.D., Chief Scientific Officer of Aldagen, will be participating in a panel titled: “Stem Cells: Translating Exciting Preclinical Data into Human Clinical Trials.” In addition to Dr. Balber, this session will include a clinician, a researcher, and a representative from the FDA who will discuss the challenges of translating preclinical stem cell data into clinical studies, and the progress that has been made to date.

On Wednesday, May 20 at 10:00 am, Tom Amick, Chairman and Chief Executive Officer of Aldagen, will be participating in a panel titled: “‘Where’s the Door? I Want to Get Out!’ Searching for the Exits.” This session will provide a discussion on financing and exit opportunities for biotech companies in the current economic climate.

About Aldagen, Inc.

Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. The company has four product candidates in clinical trials. Aldagen’s most advanced product candidate, ALD-101, is currently in a pivotal Phase 3 clinical trial to evaluate its efficacy in improving umbilical cord blood transplants used to treat inherited metabolic diseases in pediatric patients. The company also is conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates: ALD 151 to improve umbilical cord blood transplants used in the treatment of leukemia, ALD-301 to treat critical limb ischemia, and ALD-201 to treat ischemic heart failure. Aldagen’s product candidates consist of specific populations of adult stem cells that the company isolates using its proprietary technology.